Human Metabolome Technologies (TSE:6090) ROCE %: 0.00% (As of Dec. 2025)


TSE:6090 Human Metabolome Technologies Inc TSE:6090
59 GF Score
Price 円598.00
GF Value 円529.55
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Human Metabolome Technologies ROCE %?

Human Metabolome Technologies TSE:6090 +0.84% 59 ROCE % is 0.00% as of Dec. 2025. GuruFocus rates TSE:6090 with a GF Score™ of 59/100 and a GF Value™ of 円529.55 (Modestly Overvalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Human Metabolome Technologies's annualized ROCE % for the quarter that ended in Dec. 2025 was 0.00%.

Human Metabolome Technologies  (TSE:6090) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Human Metabolome Technologies ROCE % Related Terms

Human Metabolome Technologies ROCE % Historical Data

* Premium members only.

The historical data trend for Human Metabolome Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Human Metabolome Technologies ROCE % Chart

Human Metabolome Technologies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Jun20 Jun21 Jun22 Jun23 Jun24
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.78 4.13 18.68 14.41 14.01

Human Metabolome Technologies Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.17 -19.37 -15.86 0.00 34.97
TSE:6090
59GF Score
Human Metabolome Technologies Inc TSE:6090
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Human Metabolome Technologies ROCE % Calculation

Human Metabolome Technologies's annualized ROCE % for the fiscal year that ended in Jun. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2024 )  (A: Jun. 2023 )(A: Jun. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2024 )  (A: Jun. 2023 )(A: Jun. 2024 )
=263.998/( ( (2291.058 - 493.007) + (2603.401 - 632.757) )/ 2 )
=263.998/( (1798.051+1970.644)/ 2 )
=263.998/1884.3475
=14.01 %

Human Metabolome Technologies's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=0/( ( (2002.803 - 300.308) + (2137.134 - 312.909) )/ 2 )
=0/( ( 1702.495 + 1824.225 )/ 2 )
=0/1763.36
=0.00 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Human Metabolome Technologies (TSE:6090) has a ROCE % of 0.00% as of Dec. 2025.
Is Human Metabolome Technologies' ROCE % too high?
Human Metabolome Technologies' current ROCE % is 0.00%. Overall, Human Metabolome Technologies has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' ROCE % compare to TMO and DHR?
Human Metabolome Technologies' ROCE % of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Human Metabolome Technologies's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Modestly Overvalued. The stock's GF Value™ is 円529.55, compared to a current price of 円598.00 — trading 12.9% above its estimated fair value. The current ROCE % is 0.00%. Human Metabolome Technologies' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current ROCE % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?

Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be overvalued. The current stock price of 円598.00 is trading 12.9% above its estimated GF Value™ of 円529.55. GuruFocus considers Human Metabolome Technologies to be Modestly Overvalued.

Key valuation signals for TSE:6090:

  • ROCE %: 0.00%
  • GF Value™: 円529.55 vs. price of 円598.00 (12.9% above fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Human Metabolome Technologies Business Description

Address Yamagata Prefecture Kakuganji Water 246-2, Tsuruoka, JPN, 997-0052
Human Metabolome Technologies Inc is involved in the search and diagnosis of biomarkers and commercialization in the field of drug development.
59GF Score

Get the complete analysis for TSE:6090

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円598.00
Price
円529.55
GF Value